Get caught up with Contemporary OB/GYN's latest coverage from The Menopause Society Annual Meeting in San Diego, California.
News|Articles|March 31, 2026
Contemporary OB/GYN's most popular headlines from Q1 2026
Author(s)Joshua Fitch, Senior Editor
Fact checked by: Benjamin P. Saylor
Take a quick look at our top 10 headlines from the first quarter of 2026.
Advertisement
Advertisement
Before we turn the calendar to the second quarter of 2026, Contemporary OB/GYN has compiled a list of our most-viewed headlines from Q1, so today’s ob-gyns and women’s health care providers can be informed as Q2 rolls in.
Related to this article
Misread Women’s Health Initiative data sidelined hormone therapy and menopause education, according to Mary Jane Minkin, MD, FACOG.
Susan Reed, MD, on the MsFLASH network's pooled findings, including nonhormonal therapies comparable to low-dose estradiol and CBT for sleep.
Late recurrence, high-risk features, and treatment failure can signal midlife night sweats aren’t menopause, according to Cheryl Cox Kinney, MD.
Hormone therapy was associated with more frequent, longer migraines in postmenopausal women, but not with greater severity or analgesic use.
JoAnn V. Pinkerton, MD, offers primary care counseling on elinzanetant's side effects and the early onset and continued relief of hot flashes.
Menopausal brain fog is common, and hormone therapy has neutral cognitive effects, according to Pauline M. Maki, PhD.
Stephanie S. Faubion, MD, on choosing between fezolinetant and elinzanetant, liver monitoring, follow-up, and open questions in menopause care.
Advertisement
Advertisement